Back to News
Market Impact: 0.2
HCW Biologics Secures up to $10.0 Million in Cash Through Debt Financing
Source: globenewswire.com
Healthcare & Biotech
Funding is intended to support completion of the HCW9302 Phase 1 study in alopecia areata and establish a Recommended Phase 2 Dose. The text provides no funding amount, study results, or timing.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- We're raising our price target on Cardinal Health after another stellar quarter of profits
- Halozyme falls 6% as raised guidance fails to impress investors
- Dentsply earnings missed by $0.02, revenue fell short of estimates
- Cigna raises annual profit forecast on strength in health services unit
- US hospitals brace for tougher 2027 as coverage losses and Medicaid cuts loom
- Truist raises Zimmer Biomet stock price target on robotics progress